Science News
from research organizations

Underuse of anti-clotting therapies common among patients with atrial fibrillation who have a stroke

Date:
March 14, 2017
Source:
The JAMA Network Journals
Summary:
Inadequate use of anticoagulation therapies was prevalent among patients with atrial fibrillation who experienced a stroke, according to a study.
Share:
FULL STORY

Inadequate use of anticoagulation therapies was prevalent among patients with atrial fibrillation who experienced a stroke, according to a study appearing in the March 14 issue of JAMA.

Atrial fibrillation (AF) is an independent risk factor for stroke, increases stroke risk by a factor of 4 to 5, and accounts for 10 percent to 15 percent of all ischemic strokes. While the burden of AF-related stroke is high, AF is a potentially treatable risk factor. Numerous studies have demonstrated that vitamin K antagonists, such as warfarin, or non-vitamin K antagonist oral anticoagulants (NOACs), reduce the risk of ischemic stroke. Based on these data, current guidelines recommend adjusted-dose warfarin or NOACs over aspirin for stroke prevention in high-risk patients with AF.

Ying Xian, M.D., Ph.D., of the Duke University Medical Center, Durham, N.C., and colleagues conducted a study that included 94,474 patients who had an acute ischemic stroke and known history of AF admitted to hospitals participating in the Get With the Guidelines-Stroke program.

Of these patients:

  • 84 percent were not receiving therapeutic anticoagulation prior to stroke
  • 30 percent were not receiving any antithrombotic treatment prior to stroke
  • 7.6 percent were receiving therapeutic warfarin
  • 8.8 percent were receiving NOACs
  • 40 percent were receiving antiplatelet therapy only

Therapeutic anticoagulation was associated with lower odds of moderate or severe stroke and lower odds of in-hospital mortality.


Story Source:

Materials provided by The JAMA Network Journals. Note: Content may be edited for style and length.


Journal Reference:

  1. Ying Xian, Emily C. O’Brien, Li Liang, Haolin Xu, Lee H. Schwamm, Gregg C. Fonarow, Deepak L. Bhatt, Eric E. Smith, DaiWai M. Olson, Lesley Maisch, Deidre Hannah, Brianna Lindholm, Barbara L. Lytle, Michael J. Pencina, Adrian F. Hernandez, Eric D. Peterson. Association of Preceding Antithrombotic Treatment With Acute Ischemic Stroke Severity and In-Hospital Outcomes Among Patients With Atrial Fibrillation. JAMA, 2017; 317 (10): 1057 DOI: 10.1001/jama.2017.1371

Cite This Page:

The JAMA Network Journals. "Underuse of anti-clotting therapies common among patients with atrial fibrillation who have a stroke." ScienceDaily. ScienceDaily, 14 March 2017. <www.sciencedaily.com/releases/2017/03/170314111125.htm>.
The JAMA Network Journals. (2017, March 14). Underuse of anti-clotting therapies common among patients with atrial fibrillation who have a stroke. ScienceDaily. Retrieved March 25, 2017 from www.sciencedaily.com/releases/2017/03/170314111125.htm
The JAMA Network Journals. "Underuse of anti-clotting therapies common among patients with atrial fibrillation who have a stroke." ScienceDaily. www.sciencedaily.com/releases/2017/03/170314111125.htm (accessed March 25, 2017).